
Humira: An injected biologic for moderate to severe plaque psoriasis. It blocks TNF, one of the main inflammation signals behind psoriasis, and is usually given as a shot under the skin every other week. Vtama: A once-daily steroid-free cream for plaque psoriasis. It can be used anywhere on the body, including the face and skin folds, and some people stay clear for months after stopping.


Choose for moderate to severe psoriasis or hidradenitis suppurativa — the first approved biologic for HS, now with cheaper biosimilars.
Choose for psoriasis or eczema anywhere on the body when you want a once-daily non-steroid with no time limit.
Can you take them together?
Vtama can be used on remaining plaques while on Humira. It does not interact with the biologic.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.










Binds TNF: Captures an immune messenger that promotes inflammation. Reduces inflammatory signaling: TNF has less ability to activate its receptors. Lets inflamed skin settle: Conditions such as psoriasis can improve over time.
Adalimumab binds TNF-alpha and inhibits its interaction with p55/p75 TNF receptors. This image focuses on skin inflammation; Humira also has other indications.

Activates AhR: Binds a receptor that helps regulate skin-cell behavior. May rebalance inflammation: Changes in immune signaling may help calm skin. May support the skin barrier: Changes in barrier proteins may help skin function.
Tapinarof is an AhR agonist; the specific therapeutic mechanisms are unknown. Anti-inflammatory and barrier effects are proposed from experimental evidence and are explicitly qualified.
Adults are not dosed by body weight. You start with a larger loading dose to get levels up fast, then settle into an every-other-week rhythm.
Starting dose: 80 mg on day one, as one 80 mg injection or two 40 mg injections at different spots.
One week later: 40 mg.
Usual dose: 40 mg every other week, the same day of the week each time.
If it stops working: Some people move to weekly injections, others switch drugs. The prescriber's call.
Other conditions: Hidradenitis suppurativa uses a heavier loading dose and weekly maintenance, so do not assume a friend's schedule matches yours.
How long: Long term, with no set course length. It continues while it works and is tolerated.
When to Apply: Once a day, at whatever time you will remember. A thin layer over the plaques, rubbed in. It can go on the face, eyelids, armpits, groin and under the breasts, which sets it apart from a steroid. Wash your hands afterwards unless your hands are being treated.
How to Start: Once daily from day one, on every plaque you want treated. No ramp-up, and no cap on how much of the body can be covered, so it does not have to be rationed the way a strong steroid does.
If It Irritates: Small red bumps around hair follicles are the most common problem and usually appear in the first few weeks. Most are not infection and often settle without stopping. Stinging or a rash where you applied it is the other pattern, and that one is worth showing your doctor, because a true contact allergy means stopping.
If It’s Not Working: There is one strength, so there is nothing to increase. Give it a full twelve weeks. If plaques are still thick then, the conversation is about adding something else, phototherapy, or moving to a tablet or injection.
Any time of day, but pick a set day of the week and keep to it. Every other week is easy to lose track of, so set a phone reminder on day one.
Take the pen or syringe out of the fridge 15 to 30 minutes before injecting. Cold liquid stings more. Do not warm it in the microwave or hot water.
Inject into the front of the thigh or the belly, at least two inches from the navel. Rotate the spot each time, and avoid skin that is bruised, red, hard, tender or scarred. Never inject through a plaque. A nurse or pharmacist should train you in person for the first dose. Used pens go in a sharps container, never the household bin.
Inject as soon as you remember, then return to your original schedule rather than shifting future doses. Never inject two doses to catch up. If you have missed more than one dose, call the prescriber before restarting — long gaps can blunt how well it works.
Everyone is screened for tuberculosis before the first dose — a skin test or TB blood test, often with a chest X-ray. TNF blockers can wake a dormant TB infection, so a positive screen is treated first and adalimumab waits until that treatment is under way. Testing is often repeated yearly, or sooner if you live somewhere TB is common.
Hepatitis B and C are checked too, because hepatitis B can reactivate when the immune signal is blocked.
After that there is no fixed blood test schedule like methotrexate's. Many doctors check a blood count and liver tests occasionally. Most monitoring is clinical — how the skin looks, and whether you are getting more infections than usual.
Skin should be checked periodically, because TNF blockers are linked to a small increase in skin cancer. The label also carries a boxed warning about serious infections and about lymphoma and other cancers, based mostly on rare cases in children and young adults. The absolute risk is low, but it is why this prescription gets regular review.
No blood tests are required. There is nothing to check on a lab report, which is one of the practical arguments for a topical over a tablet.
Monitoring is a look at the skin and a conversation, usually at about twelve weeks. Two things get asked about: folliculitis, and whether it is a few bumps or enough to be a problem; and whether the treated skin has become itchy and inflamed in a new way, which points to contact dermatitis rather than psoriasis.
Long term there is no organ risk to track and no skin thinning to watch for, so there is no maximum duration. What is genuinely not known yet is what many years of continuous use looks like, because the drug is recent. A common pattern is to treat until clear, stop, and restart when plaques come back.
Approximate windows, not promises.
First few minutesThe injection: A sting for a few seconds. Injection site reactions, if they happen, show up in the first weeks.
First few minutesApplying it: A thin layer once a day on the plaques.
Weeks 1 to 4Starting: Itching often eases before the plaques look different, and some people see the scale thin early.
Weeks 1 to 4Starting: Scale and roughness ease before the redness does, often by week four. Folliculitis shows up now if it is going to, usually small tender bumps in hair-bearing areas.
Weeks 4 to 12Working: Plaques flatten, scale lifts and redness fades from the middle outward. Most of the visible change happens here. Psoriatic arthritis improves on a similar timeline, and hidradenitis suppurativa settles to fewer painful lumps on its own heavier schedule.
Week 16Judge it here: The point the trials measured. Most people reached at least a 75 percent improvement in skin involvement and severity, and a smaller share cleared almost completely.
Months 6 to 12Nails: The slowest, because a nail takes months to grow out. Pitting and lifting improve well after the skin has settled.
After the first yearLong term: Most people who respond keep responding.
Weeks 4 to 8Working: Plaques flatten and shrink, and color fades from red toward pink or brown.
Weeks 8 to 12Judge it here: Trials measured their main result at twelve weeks, and many people were still improving then. A meaningful minority reached clear or almost clear skin — a realistic target, not a promise.
After stoppingRemission: Unlike a steroid, it does not usually rebound. People who cleared completely often stayed clear for months before restarting.
Sorted by what to do about them.
The list price is very high, tens of thousands of dollars a year. Almost nobody pays that. What you pay depends on your insurance, and getting there takes paperwork.
Prior authorization is close to universal. Most plans require you to have tried and failed something cheaper first — phototherapy, methotrexate or another systemic drug — and they want records to prove it.
Biosimilars changed the picture. Several have been sold in the United States since 2023, some at much lower list prices. Which one you get is usually decided by your plan's formulary, not your dermatologist, and plans switch year to year. A switch is a paperwork event, not a medical downgrade, though you may need retraining on a different pen.
Manufacturer copay cards can bring the cost down to very little with commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or with no insurance, manufacturer and foundation assistance programs are the usual route, and their rules change often.
Brand only, with no generic. It is one of the more expensive topicals for psoriasis and costs far more than a generic steroid or generic calcipotriene.
Coverage varies and prior authorization is common; plans frequently want to see a topical steroid, and often a vitamin D analog, tried first. Manufacturer copay cards exist and the terms change, so check the current one.
Because a tube covers only so much, cost climbs quickly with widespread psoriasis, which is one of the main reasons people end up on a tablet or injection instead.
A large protein grown in living cells rather than a factory chemical. That is why it is injected, and why it lives in the fridge.
A sharp sting for a few seconds. Letting it warm to room temperature first makes a real difference, and citrate-free versions sting less than the original.
Some change by 4 weeks, and about 16 weeks before you judge it fairly. If nothing has happened by then, talk about switching.
Yes, apart from live ones. The flu shot, COVID, pneumonia vaccines and Shingrix are fine and usually recommended. Have live vaccines before you start.
A simple cold is usually not a reason to skip a dose. Anything with a fever, or needing antibiotics, should be checked with the prescriber first.
It must be shown to have no clinically meaningful difference from the original. The pen changes; what is inside does the same job.
No. It works on a different switch inside the skin cell, the aryl hydrocarbon receptor. That is why there is no time limit and no skin thinning.
Yes — approved for the face and skin folds, one of its main advantages over a steroid.
Most likely folliculitis — small red bumps around hair follicles where you applied it. The most common side effect in the trials, at roughly one in five people, usually mild, and most carried on.
Give it twelve weeks. Some change usually shows by four.
That is a normal way to use it. In the long-term study, many who cleared completely stayed clear for months, then restarted when plaques returned.
Yes, it is also approved for atopic dermatitis, in adults and in children from age two.